Terms: = Ovarian cancer AND DNMT3A, Q9Y6K1, 1788, ENSG00000119772, DNMT3A2, M_HsaIIIA AND Diagnosis
4 results:
1. miR-29c-3p acts as a tumor promoter by regulating β-catenin signaling through suppressing dnmt3a, TET1 and HBP1 in ovarian carcinoma.
Zhao H; Feng L; Cheng R; Wu M; Bai X; Fan L; Liu Y
Cell Signal; 2024 Jan; 113():110936. PubMed ID: 37925048
[TBL] [Abstract] [Full Text] [Related]
2. Clonal Hematopoiesis-Associated Gene Mutations in a Clinical Cohort of 448 Patients With ovarian cancer.
Weber-Lassalle K; Ernst C; Reuss A; Möllenhoff K; Baumann K; Jackisch C; Hauke J; Dietrich D; Borde J; Park-Simon TW; Hanker L; Prieske K; Schmidt S; Weber-Lassalle N; Pohl-Rescigno E; Kommoss S; Marmé F; Heitz F; Stingl JC; Schmutzler RK; Harter P; Hahnen E
J Natl Cancer Inst; 2022 Apr; 114(4):565-570. PubMed ID: 34963005
[TBL] [Abstract] [Full Text] [Related]
3. miR-145 promotes miR-133b expression through c-myc and dnmt3a-mediated methylation in ovarian cancer cells.
Li J; Zhang S; Zou Y; Wu L; Pei M; Jiang Y
J Cell Physiol; 2020 May; 235(5):4291-4301. PubMed ID: 31612498
[TBL] [Abstract] [Full Text] [Related]
4. Somatic variants in epigenetic modifiers can predict failure of response to imatinib but not to second-generation tyrosine kinase inhibitors.
Nteliopoulos G; Bazeos A; Claudiani S; Gerrard G; Curry E; Szydlo R; Alikian M; Foong HE; Nikolakopoulou Z; Loaiza S; Khorashad JS; Milojkovic D; Perrotti D; Gale RP; Foroni L; Apperley JF
Haematologica; 2019 Dec; 104(12):2400-2409. PubMed ID: 31073075
[TBL] [Abstract] [Full Text] [Related]
